{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:49:27Z","timestamp":1793227767796,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12325-025-03183-x","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:28:45Z","timestamp":1746502125000},"page":"2708-2727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn\u2019s Disease: A Network Meta-Analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Tim","family":"Disher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Naessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4027-1254","authenticated-orcid":false,"given":"Myrlene","family":"Sanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Bonner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-8776","authenticated-orcid":false,"given":"Meaghan","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-5577","authenticated-orcid":false,"given":"Becky","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Allegretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-054X","authenticated-orcid":false,"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"3183_CR1","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/ijms24021526","volume":"24","author":"A Saez","year":"2023","unstructured":"Saez A, Herrero-Fernandez B, Gomez-Bris R, Sanchez-Martinez H, Gonzalez-Granado JM. Pathophysiology of inflammatory bowel disease: innate immune system. Int J Mol Sci. 2023;24:1526.","journal-title":"Int J Mol Sci"},{"key":"3183_CR2","doi-asserted-by":"publisher","first-page":"10890","DOI":"10.1038\/s41598-022-13222-0","volume":"12","author":"AZ Yang","year":"2022","unstructured":"Yang AZ, Jostins-Dean L. Environmental variables and genome-environment interactions predicting IBD diagnosis in large UK cohort. Sci Rep. 2022;12:10890.","journal-title":"Sci Rep"},{"key":"3183_CR3","first-page":"661","volume":"98","author":"B Veauthier","year":"2018","unstructured":"Veauthier B, Hornecker JR. Crohn\u2019s disease: diagnosis and management. Am Fam Physician. 2018;98:661\u20139.","journal-title":"Am Fam Physician"},{"key":"3183_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113:481\u2013517.","journal-title":"Am J Gastroenterol"},{"key":"3183_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, et al. Crohn\u2019s disease. Nat Rev Dis Primers. 2020;6:22.","journal-title":"Nat Rev Dis Primers"},{"key":"3183_CR6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.cgh.2023.05.002","volume":"22","author":"S Hutfless","year":"2024","unstructured":"Hutfless S, Jasper RA, Chen PH, Joseph S, Miller S, Brant SR. Burden of Crohn\u2019s disease in the United States Medicaid population, 2010\u20132019. Clin Gastroenterol Hepatol. 2024;22:1087-97.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3183_CR7","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.12688\/f1000research.18902.1","volume":"8","author":"M Samaan","year":"2019","unstructured":"Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn\u2019s disease: optimising the old and maximising the new. F1000Res. 2019;8:1210.","journal-title":"F1000Research"},{"key":"3183_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12876-023-02675-w","volume":"23","author":"TH Gibble","year":"2023","unstructured":"Gibble TH, Naegeli AN, Grabner M, et al. Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn\u2019s disease and ulcerative colitis in the United States. BMC Gastroenterol. 2023;23:63.","journal-title":"BMC Gastroenterol"},{"key":"3183_CR9","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","volume":"16","author":"GW Sewell","year":"2022","unstructured":"Sewell GW, Kaser A. Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention. J Crohns Colitis. 2022;16:ii3\u201319.","journal-title":"J Crohns Colitis"},{"key":"3183_CR10","doi-asserted-by":"crossref","unstructured":"Panaccione S, Danese S, Feagan B, et al. Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn\u2019s disease: results of the GALAXI 2 & 3 phase 3 studies. Presented at Digestive Disease Week; May 18\u201321, 2024; Washington, DC, USA.","DOI":"10.1016\/S0016-5085(24)05019-4"},{"key":"3183_CR11","doi-asserted-by":"crossref","unstructured":"Sands BE, D\u2019Haens G, Danese S, et al. Efficacy of guselkumab versus placebo in Crohn\u2019s disease based on prior response\/exposure to biologic therapy: results of the GALAXI 2 & 3 phase 3 studies. Presented at United European Gastroenterology Week; October 12\u201315, 2024; Vienna, Austria.","DOI":"10.14309\/01.ajg.0001035148.34102.cf"},{"key":"3183_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions, 2nd edn. Chichester: Wiley; 2019.","edition":"2"},{"key":"3183_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"3183_CR14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jval.2024.05.015","volume":"27","author":"S Tanaka","year":"2024","unstructured":"Tanaka S, Igarashi A, De Moor R, et al. A targeted review of worldwide indirect treatment comparison guidelines and best practices. Value Health. 2024;27:1179\u201390.","journal-title":"Value Health"},{"key":"3183_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1741-7015-12-93","volume":"12","author":"S Cope","year":"2014","unstructured":"Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12:93.","journal-title":"BMC Med"},{"key":"3183_CR16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1177\/0272989X17711933","volume":"37","author":"C Cameron","year":"2017","unstructured":"Cameron C, Ewara E, Wilson FR, et al. The importance of considering differences in study design in network meta-analysis: an application using anti-tumor necrosis factor drugs for ulcerative colitis. Med Decis Making. 2017;37:894\u2013904.","journal-title":"Med Decis Making"},{"key":"3183_CR17","unstructured":"NICE. Ustekinumab for treating moderately to severely active ulcerative colitis. https:\/\/www.nice.org.uk\/guidance\/ta633."},{"key":"3183_CR18","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Minozzi S, Kopylov U, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2024;18:1531\u201355.","journal-title":"J Crohns Colitis"},{"key":"3183_CR19","unstructured":"Plummer M. JAGS: just another Gibbs sampler. https:\/\/mcmc-jags.sourceforge.io\/."},{"key":"3183_CR20","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"3183_CR21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/sim.6381","volume":"34","author":"RM Turner","year":"2015","unstructured":"Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JP. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Stat Med. 2015;34:984\u201398.","journal-title":"Stat Med"},{"key":"3183_CR22","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/aje\/kwab278","volume":"191","author":"G Salanti","year":"2022","unstructured":"Salanti G, Nikolakopoulou A, Efthimiou O, Mavridis D, Egger M, White IR. Introducing the treatment hierarchy question in network meta-analysis. Am J Epidemiol. 2022;191:930\u20138.","journal-title":"Am J Epidemiol"},{"key":"3183_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. Risankizumab versus ustekinumab for patients with moderate to severe Crohn\u2019s disease: results from the phase 3B SEQUENCE study. N Engl J Med. 2024;391:213\u201323.","journal-title":"N Engl J Med"},{"key":"3183_CR24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u201395.","journal-title":"N Engl J Med"},{"key":"3183_CR25","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","volume":"6","author":"S Singh","year":"2021","unstructured":"Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:1002\u201314.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3183_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/03007995.2019.1580094","volume":"35","author":"A Varu","year":"2019","unstructured":"Varu A, Wilson FR, Dyrda P, Hazel M, Hutton B, Cameron C. Treatment sequence network meta-analysis in Crohn\u2019s disease: a methodological case study. Curr Med Res Opin. 2019;35:733\u201356.","journal-title":"Curr Med Res Opin"},{"key":"3183_CR27","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.3748\/wjg.v23.i35.6385","volume":"23","author":"A Vasudevan","year":"2017","unstructured":"Vasudevan A, Gibson PR, van Langenberg DR. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told? World J Gastroenterol. 2017;23:6385\u2013402.","journal-title":"World J Gastroenterol"},{"key":"3183_CR28","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/jrsm.1700","volume":"15","author":"AE Ades","year":"2024","unstructured":"Ades AE, Welton NJ, Dias S, Phillippo DM, Caldwell DM. Twenty years of network meta-analysis: continuing controversies and recent developments. Res Synth Methods. 2024;15:702\u201327.","journal-title":"Res Synth Methods"},{"key":"3183_CR29","unstructured":"Data on file. GALAXI 1 clinical study report."},{"key":"3183_CR30","unstructured":"Data on file. GALAXI 2 clinical study report."},{"key":"3183_CR31","unstructured":"Data on file. GALAXI 3 clinical study report."},{"key":"3183_CR32","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20139.","journal-title":"Lancet"},{"key":"3183_CR33","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015\u201330.","journal-title":"Lancet"},{"key":"3183_CR34","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399:2031\u201346.","journal-title":"Lancet"},{"key":"3183_CR35","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","volume":"142","author":"P Rutgeerts","year":"2012","unstructured":"Rutgeerts P, van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102\u201311.","journal-title":"Gastroenterology"},{"key":"3183_CR36","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2005;353:1912\u201325.","journal-title":"N Engl J Med"},{"key":"3183_CR37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369:711\u201321.","journal-title":"N Engl J Med"},{"key":"3183_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med. 2007;357:228\u201338.","journal-title":"N Engl J Med"},{"key":"3183_CR39","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399:2200\u201311.","journal-title":"Lancet"},{"key":"3183_CR40","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Panes J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388:1966\u201380.","journal-title":"N Engl J Med"},{"key":"3183_CR41","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360.","journal-title":"N Engl J Med"},{"key":"3183_CR42","unstructured":"Ferrante M, Danese S, Chen M, et al. Primary efficacy and safety of mirikizumab in moderate to severe Crohn\u2019s disease: results of the treat-through VIVID 1 study. Presented at the 18th Congress of the European Crohn\u2019s and Colitis Organisation; March 1-4, 2023; Copenhagen, Denmark."},{"key":"3183_CR43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","volume":"162","author":"BE Sands","year":"2022","unstructured":"Sands BE, Peyrin-Biroulet L, Kierkus J, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease. Gastroenterology. 2022;162:495\u2013508.","journal-title":"Gastroenterology"},{"key":"3183_CR44","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N Engl J Med. 2012;367:1519\u201328.","journal-title":"N Engl J Med"},{"key":"3183_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365.","journal-title":"Gastroenterology"},{"key":"3183_CR46","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323\u201333 (quiz 591).","journal-title":"Gastroenterology"},{"key":"3183_CR47","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial. Gut. 2007;56:1232\u20139.","journal-title":"Gut"},{"key":"3183_CR48","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/j.1365-2036.2010.04360.x","volume":"32","author":"SB Hanauer","year":"2010","unstructured":"Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn\u2019s disease. Aliment Pharmacol Ther. 2010;32:384\u201393.","journal-title":"Aliment Pharmacol Ther"},{"key":"3183_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease. N Engl J Med. 2024;391:213\u201323.","journal-title":"N Engl J Med"},{"key":"3183_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","volume":"16","author":"S Vermeire","year":"2022","unstructured":"Vermeire S, D\u2019Haens G, Baert F, et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis. 2022;16:27\u201338.","journal-title":"J Crohns Colitis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03183-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03183-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03183-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T09:03:44Z","timestamp":1747472624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03183-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3183"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03183-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tim Disher, Meaghan Bartlett, Becky Hooper, Jenna Ellis, and Ashley Bonner are current or former employees of EVERSANA. Myrlene Sanon, Dominik Naessen, and Zijiang Yang are employees of Johnson & Johnson and may hold stock\/stock options in Johnson & Johnson. Drs. Axel Dignass and Jessica R.\u00a0Allegretti have received personal compensation from Janssen for consultant fees. Axel\u00a0Dignass reports fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis, and endpoint committees from Abivax, AbbVie, Bristol Myers Squibb, Dr Falk Pharma, Galapagos, Gilead, Janssen, and Pfizer; consultancy fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dr Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, J&J, Lilly, MSD, Pfizer, Pharmacosmos, Sandoz, Stada, Takeda, Tillotts, and Vifor Pharma; payment from lectures including service on speakers bureaus from AbbVie, Biogen, CED Service GmbH, Celltrion, Falk Foundation, Ferring, Galapagos, Gilead, High5MD, Janssen, Materia Prima, MedToday, MSD, Pfizer, Streamed-Up, Takeda, Tillotts, and Vifor Pharma; and payment for manuscript preparation from Falk Foundation, Takeda, Thieme, and UniMed Verlag. Preparation of this manuscript was funded by Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This analysis and summary are based on previously completed\/published trials and do not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}